Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose

by Vandana Singh, Benzinga Editor

June 9, 2021 8:37 AM | 28 seconds read | Make a Comment

The FDA has accepted for review Adamis Pharmaceuticals Corporation's ADMP marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.
The agency's target action date is November 12.
The company resubmitted the application in May after it received a complete response letter in November 2020.
Related content: Benzinga's Full FDA Calendar.
Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.